ArticleFrontiers in microbiology2012
Nitric oxide releasing nanoparticles for treatment of Candida albicans burn infections.
Article in Frontiers in microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 69 citations in OpenAlex.
- Article
- Nitric oxide-releasing responsive biomaterials for antimicrobial skin therapy.Redox biology · 2026Review
- Nitric Oxide-Releasing Gels in the Context of Antimicrobial Stewardship, Biofilm Management, and Wound-Repair Biology.Antibiotics (Basel, Switzerland) · 2026Review
- Nitric Oxide-Releasing Microparticles: A Novel Treatment for Onychomycosis.Molecular pharmaceutics · 2025Article
- In vitro and preclinical evaluation of the antifungal activity of 6-methoxy-1 H-indole-2-carboxylic acid produced by Bacillus toyonensis strain OQ071612 formulated as nanosponge hydrogel.Microbial cell factories · 2025Article
- Nanosponge hydrogel of octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl) propanoate of Alcaligenes faecalis.Applied microbiology and biotechnology · 2024Article
- Impact of Nitric Oxide-Release Kinetics on Antifungal Activity.Journal of fungi (Basel, Switzerland) · 2024Article
- Micro- and nanoparticles as platforms for the treatment of fungal infections: present and future perspectives.Future microbiology · 2023Article
- Development of Novel Amphotericin B-Immobilized Nitric Oxide-Releasing Platform for the Prevention of Broad-Spectrum Infections and Thrombosis.ACS applied materials & interfaces · 2021Article
- Nitric Oxide-Releasing Nanoparticles Are Similar to Efinaconazole in Their Capacity to EradicateFrontiers in cellular and infection microbiology · 2021Article
- Cutaneous candidiasis caused byThe Pan African medical journal · 2021Article
- Nitric Oxide-ReleasingPharmaceutics · 2020Article
- The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications.Biochemical pharmacology · 2020Review
- Recent Advances in Nanomaterial-Based Wound-Healing Therapeutics.Pharmaceutics · 2020Review
- The potential of respiration inhibition as a new approach to combat human fungal pathogens.Current genetics · 2019Review
- Article
- Sustained Nitric Oxide-Releasing Nanoparticles Interfere with Methicillin-Resistant Staphylococcus aureus Adhesion and Biofilm Formation in a Rat Central Venous Catheter Model.Antimicrobial agents and chemotherapy · 2017Article
- Article
- Endogenous nitric oxide accumulation is involved in the antifungal activity of Shikonin against Candida albicans.Emerging microbes & infections · 2016Article
- Nanoparticle-Based Therapies for Wound Biofilm Infection: Opportunities and Challenges.IEEE transactions on nanobioscience · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans is a leading fungal cause of burn infections in hospital settings, and sepsis is one of the principle causes of death after a severe burn. The prevalence of invasive candidiasis in burn cases varies widely, but it accounts for 3-23% of severe infection with a mortality rate ranging from 14 to 70%. Therefore, it is imperative that we develop innovative therapeutics to which this fungus is unlikely to evolve resistance, thus curtailing the associated morbidity and mortality and ultimately improving our capacity to treat these infections. An inexpensive and stable nitric oxide (NO)-releasing nanoparticle (NO-np) platform has been recently developed. NO is known to have direct antifungal activity, modulate host immune responses and significantly regulate wound healing. In this study, we hypothesized that NO-np would be an effective therapy in the treatment of C. albicans burn infections. Using a murine burn model, NO-np demonstrated antifungal activity against C. albicans in vivo, most likely by arresting its growth and morphogenesis as demonstrated in vitro. NO-np demonstrated effective antimicrobial activity against yeast and filamentous forms of the fungus. Moreover, we showed that NO-np significantly accelerated the rate of wound healing in cutaneous burn infections when compared to controls. The histological evaluation of the affected tissue revealed that NO-np treatment modified leukocyte infiltration, minimized the fungal burden, and reduced collagen degradation, thus providing potential mechanisms for the therapeutics' biological activity. Together, these data suggest that NO-np have the potential to serve as a novel topical antifungal which can be used for the treatment of cutaneous burn infections and wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.